Molecular characterization of apocrine salivary duct carcinoma

American Journal of Surgical Pathology

Volumn 39, Issue 6, 2015, Pages 744-752

  Chiosea, Simion I ^a   Williams, Lindsay ^a   Griffith, Christopher C ^a   Thompson, Lester D R ^c   Weinreb, Ilan ^d   Bauman, Julie E ^b   Luvison, Alyssa ^a   Roy, Somak ^a   Seethala, Raja R ^a   Nikiforova, Marina N ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ERBB2 (HER2); next generation sequencing; PIK3CA; salivary duct carcinoma; TP53

Indexed keywords

AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PATHOLOGY; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS;

AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS;

EID: 84929866424     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000410     Document Type: Article

References (48)

1. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72:1503-1512.
2. Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: A report of 50 cases. Cancer. 2005;103:2526-2533.
3. Guzzo M, Di Palma S, Grandi C, et al. Salivary duct carcinoma: Clinical characteristics and treatment strategies. Head Neck. 1997; 19:126-133.
4. Williams MD, Roberts D, Blume nschein GR Jr, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: Biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31: 1645-1652.
5. Hosal AS, Fan C, Barnes L, et al. Salivary duct carcinoma. Otolaryngol Head Neck Surg. 2003;129:720-725.
6. Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009;123:250-252.
7. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review. Med Oncol. 2012;29:704-706.
8. Jaspers HC, Verbist BM, Schoffelen R, et al. Androgen receptorpositive salivary d uct carcinoma: A disease entity with promising new treatment options. J Clin Oncol. 2011;29:e473-e476.
9. Griffith CC, Seethala RR, Luvison A, et al. PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol. 2013;37:1201-1207.
10. Nardi V, Sadow PM, Juric D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatmen t. Clin Cancer Res. 2013;19:480-490.
11. Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106:719-726.
12. Cros J, Sbidian E, Hans S, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. An n Oncol. 2013;24:2624-2629.
13. Dogan S, Katabi N, Yelensky R, et al. Salivary duct carcinoma: Actionable somatic mutations identified by massively parallel sequencing. Lab Invest. 2013;93:S1. 306A-306A.
14. Ku B, Jung H, Sun JM, et al. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 2014;12:299.
15. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol. 1998;11:1033-1038.
16. Griffith CC, Thomps on LD, Assaad A, et al. Salivary duct carcinoma and the concept of " early carcinoma ex pleomorphic adenoma." Histopathology. 2014;65:854-860.
17. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer; 2009.
18. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
19. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast c ancer. Arch Pathol Lab Med. 2010;134:907-922.
20. Boyle DP, McArt DG, Irwin G, et al. The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology. 2014;65:340-352.
21. Pollack IF Hamilton RL James CD et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006. 105. 418-424.
22. Chiosea SI, Grandis JR, Lui VW, et al. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer. 2013;13:602.
23. Prince ME, Ubell ML, Castro J, et al. Tissue-preserving approach to extracting DNA from paraffin-embedded specimens using tissue microarray technology. Head Neck. 2007;29:465-471.
24. Roy S, Durso MB, Wald A, et al. SeqReporter: Automating nextgeneration sequencing result interpretation and reporting workflow in a clinical laboratory. J Mol Diagn. 2014;16:11-22.
25. Liu X, Jian X, Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Hum Mutat. 2011;32:894-899.
26. Hurst CD, Zuiverloon TC, Hafner C, et al. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes. 2009;2:66.
27. Adackapara CA, Sholl LM, Barletta J A, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013;63:187-193.
28. Roijer E, Nordkvist A, Strom AK, et al. Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol. 2002;160: 433-440.
29. Persson F, Andren Y, Winnes M, et al. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer. 2009;48:69-82.
30. Bahrami A, Perez-Ordonez B, Dalton JD, et al. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions. Histopathology. 2013;63:2 50-262.
31. Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294-300.
32. Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014 ;32:3212-3220.
33. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12: 395-402.
34. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
35. Lehmann BD, Bauer JA, Chen X, et al. Id entification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
36. Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013;19:6380-6388.
37. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660-4671.
38. Dumay A, Feugeas JP, Wittmer E, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2013;132: 1227-1231.
39. Masubuchi T, Tada Y, Maruya SI, et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015;20:35-44.
40. Di Palma S, Simpson RH, Marchio C, et al. Salivary duct carcinomas can be classified into luminal androgen receptorpositive, HER2 and basal-like phenotypes. Histopathology. 2012; 61:629-643.
41. Mazumdar T, Byers LA, Ng PK, et al. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. Mol Cancer Ther. 2014;13:2738-2750.
42. Soussi T, Leroy B, Taschner PE. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. Hum Mutat. 2014;35:766-778.
43. Faille A De Cremoux P Extra JM et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994 69 1145-1150.
44. Stenman G, Persson F, And ersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50:683-690.
45. Gluck S, Ross JS, Royce M, et al. TP53 genomics pr edict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/-trastuzumab. Breast Cancer Res Treat. 2012;132:781-791.
46. Di Leo A, Tanner M , Desmedt C, et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol. 2007;18:997-1003.
47. Ko YH, Roh JH, Son YI, et al. Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas. J Oral Pathol Med. 2010;39:349-355.
48. Katoh M, Nakagama H. FGF receptors: Cancer biology and therapeutics. Med Res Rev. 2014;34:280-300.